Ładuje się......
Novel formulation of cytarabine and daunorubicin: A new hope in AML treatment
Acute myeloid leukemia (AML) treatment has always been a challenge to the treating physician. Continuous efforts are being made to improve treatment outcomes in AML. CPX-351 is a pharmacologic advancement in this direction. It is a liposomal fixed drug combination of cytarabine and daunorubicin. Ear...
Zapisane w:
| Wydane w: | South Asian J Cancer |
|---|---|
| 1. autor: | |
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
Medknow Publications & Media Pvt Ltd
2015
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4382783/ https://ncbi.nlm.nih.gov/pubmed/25839020 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/2278-330X.149950 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|